• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
【24h】

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

机译：贝伐单抗改善复发性胶质母细胞瘤患者的生活质量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To quantify the benefits in survival and quality of life in patients receiving bevacizumab (BEV) for recurrent glioblastoma (GBM).Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single institution. All patients had initial treatment with surgery, radiation, and concurrent temozolomide, then monthly temozolomide. Over 250 charts were screened. Sufficient data was available for 20 patients treated with BEV and 20 patients who did not receive BEV at the time of recurrence. The independent living score (ILS), designed to reward long-term independent survival, was calculated for each patient.Results. The mean ILS was nearly double in the BEV group compared to the No-BEV group (15.0 versus 8.2,P=0.002,t-test). Two months after initiation of therapy, the median steroid dose dropped by over 90% in patients treated with BEV, but doubled in the NoBEV group. Median survival from the time of recurrence was significantly affected: 10.6 months in the BEV group versus 4.2 months (P<0.001, log rank survival) in the NoBEV group.Conclusions. BEV increases independent living and lengthens overall survival after GBM recurrence. Reduction in steroid dose may contribute to prolonged independence.
机译：目的。为了量化接受贝伐单抗（BEV）治疗复发性胶质母细胞瘤（GBM）的患者在生存和生活质量方面的益处。这是一项回顾性研究，研究对象是2005年至2009年之间在单一机构接受治疗的40例成人GBM复发患者。所有患者均先接受手术，放疗和并发替莫唑胺治疗，然后每月接受替莫唑胺治疗。筛选了250多个图表。有足够的数据可用于20例接受BEV治疗的患者和20例在复发时未接受BEV的患者。计算每位患者的独立生活得分（ILS），旨在奖励长期独立生存。与无BEV组相比，BEV组的平均ILS几乎翻了一番（15.0对8.2，P = 0.002，t检验）。开始治疗两个月后，接受BEV治疗的患者的类固醇中位剂量下降了90％以上，而NoBEV组则增加了一倍。复发时的中位生存期受到显着影响：BEV组为10.6个月，而NoBEV组为4.2个月（P <0.001，对数秩生存）。 BEV复发后，BEV可增加独立生活并延长总体生存期。减少类固醇剂量可能有助于延长独立性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号